{
  "subject": "1f8038abe267516686984319aba3cda8be760154bc23c43f267948e46d24e195",
  "claims": [
    {
      "id": "title",
      "proposition": {
        "predicate": "title",
        "object": "Early-Phase IND Protocol Recommendations for Solid Tumors; Draft Guidance for Industry; Availability"
      },
      "time": {
        "asserted": "2026-11-12T21:30:47.088Z"
      },
      "force": "quotes",
      "provenance": {
        "witness": "https://www.federalregister.gov",
        "method": "quoted collector metadata from an original HTTP response",
        "citation": "https://www.federalregister.gov/documents/2026/11/12/2026-22970/early-phase-ind-protocol-recommendations-for-solid-tumors-draft-guidance-for-industry-availability",
        "sourceDigest": "sha256:be28a42f3dceaf0a984518966928a87d5626f2fa3836d1673cc2514c9838dfbc"
      },
      "status": "unverified"
    },
    {
      "id": "summary",
      "proposition": {
        "predicate": "summary",
        "object": "The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry titled \"Early-Phase IND Protocol Recommendations for Solid Tumors.\" The purpose of this draft guidance is to provide recommendations to sponsors and clinical investigators developing early-phase trials, which include first-in- human (FIH) protocols or protocols for drugs and biologic products with limited human experience, submitted under an Investigational New Drug Application (IND) to the appropriate disease-specific division located within the Office of Oncologic Diseases (OOD) in the Center for Drug Evaluation and Research (CDER) and the Office of Clinical Evaluation (OCE) in the Center for Biologics Evaluation and Research (CBER.) This draft guidance is specific to solid tumors and does not address protocols for investigational drugs intended to treat hematologic malignancies."
      },
      "time": {
        "asserted": "2026-11-12T21:30:47.088Z"
      },
      "force": "quotes",
      "provenance": {
        "witness": "https://www.federalregister.gov",
        "method": "quoted collector metadata from an original HTTP response",
        "citation": "https://www.federalregister.gov/documents/2026/11/12/2026-22970/early-phase-ind-protocol-recommendations-for-solid-tumors-draft-guidance-for-industry-availability",
        "sourceDigest": "sha256:be28a42f3dceaf0a984518966928a87d5626f2fa3836d1673cc2514c9838dfbc"
      },
      "status": "unverified"
    },
    {
      "id": "url",
      "proposition": {
        "predicate": "url",
        "object": "https://www.federalregister.gov/documents/2026/11/12/2026-22970/early-phase-ind-protocol-recommendations-for-solid-tumors-draft-guidance-for-industry-availability"
      },
      "time": {
        "asserted": "2026-11-12T21:30:47.088Z"
      },
      "force": "quotes",
      "provenance": {
        "witness": "https://www.federalregister.gov",
        "method": "quoted collector metadata from an original HTTP response",
        "citation": "https://www.federalregister.gov/documents/2026/11/12/2026-22970/early-phase-ind-protocol-recommendations-for-solid-tumors-draft-guidance-for-industry-availability",
        "sourceDigest": "sha256:be28a42f3dceaf0a984518966928a87d5626f2fa3836d1673cc2514c9838dfbc"
      },
      "status": "unverified"
    },
    {
      "id": "source-subject",
      "proposition": {
        "predicate": "source-subject",
        "object": "federal-register:2026-22970"
      },
      "time": {
        "asserted": "2026-11-12T21:30:47.088Z"
      },
      "force": "quotes",
      "provenance": {
        "witness": "https://www.federalregister.gov",
        "method": "quoted collector metadata from an original HTTP response",
        "citation": "https://www.federalregister.gov/documents/2026/11/12/2026-22970/early-phase-ind-protocol-recommendations-for-solid-tumors-draft-guidance-for-industry-availability",
        "sourceDigest": "sha256:be28a42f3dceaf0a984518966928a87d5626f2fa3836d1673cc2514c9838dfbc"
      },
      "status": "unverified"
    },
    {
      "id": "source-edition",
      "proposition": {
        "predicate": "source-edition",
        "object": "ni:///sha-256;zvUw-rkJlggLrEHsB-nfwsEy1nadsePlB4EN_gF9xsw"
      },
      "time": {
        "asserted": "2026-11-12T21:30:47.088Z"
      },
      "force": "quotes",
      "provenance": {
        "witness": "https://www.federalregister.gov",
        "method": "quoted collector metadata from an original HTTP response",
        "citation": "https://www.federalregister.gov/documents/2026/11/12/2026-22970/early-phase-ind-protocol-recommendations-for-solid-tumors-draft-guidance-for-industry-availability",
        "sourceDigest": "sha256:be28a42f3dceaf0a984518966928a87d5626f2fa3836d1673cc2514c9838dfbc"
      },
      "status": "unverified"
    },
    {
      "id": "source-metadata",
      "proposition": {
        "predicate": "source-metadata",
        "object": {
          "subject": "federal-register:2026-22970",
          "revision": "ni:///sha-256;zvUw-rkJlggLrEHsB-nfwsEy1nadsePlB4EN_gF9xsw",
          "documentNumber": "2026-22970",
          "documentUrl": "https://www.federalregister.gov/documents/2026/11/12/2026-22970/early-phase-ind-protocol-recommendations-for-solid-tumors-draft-guidance-for-industry-availability",
          "title": "Early-Phase IND Protocol Recommendations for Solid Tumors; Draft Guidance for Industry; Availability",
          "documentType": "Notice",
          "publicationDate": "2026-11-12",
          "publicationDatePrecision": "civil-day",
          "agencies": [
            "Food and Drug Administration",
            "Health and Human Services Department"
          ],
          "abstract": "The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry titled \"Early-Phase IND Protocol Recommendations for Solid Tumors.\" The purpose of this draft guidance is to provide recommendations to sponsors and clinical investigators developing early-phase trials, which include first-in- human (FIH) protocols or protocols for drugs and biologic products with limited human experience, submitted under an Investigational New Drug Application (IND) to the appropriate disease-specific division located within the Office of Oncologic Diseases (OOD) in the Center for Drug Evaluation and Research (CDER) and the Office of Clinical Evaluation (OCE) in the Center for Biologics Evaluation and Research (CBER.) This draft guidance is specific to solid tumors and does not address protocols for investigational drugs intended to treat hematologic malignancies.",
          "commentsCloseOn": "2027-01-11",
          "commentDeadlineFieldRequested": true,
          "effectiveOn": null,
          "sourceAction": "Notice of availability.",
          "federalRegisterCitation": "91 FR 72873",
          "docketIds": [
            "Docket No. FDA-2026-D-13432"
          ],
          "regulationIdNumbers": [],
          "cfrReferences": [],
          "correctionOf": null,
          "corrections": [],
          "source": {
            "originalApiUrl": "https://www.federalregister.gov/api/v1/documents.json?conditions%5Bpublication_date%5D%5Bgte%5D=2026-11-05&conditions%5Bpublication_date%5D%5Blte%5D=2026-11-12&per_page=100&page=2&order=newest&fields%5B%5D=document_number&fields%5B%5D=title&fields%5B%5D=type&fields%5B%5D=abstract&fields%5B%5D=html_url&fields%5B%5D=publication_date&fields%5B%5D=agencies&fields%5B%5D=comments_close_on&fields%5B%5D=effective_on&fields%5B%5D=action&fields%5B%5D=citation&fields%5B%5D=regulation_id_numbers&fields%5B%5D=cfr_references&fields%5B%5D=docket_ids&fields%5B%5D=correction_of&fields%5B%5D=corrections",
            "originalResponseDigest": "sha256:be28a42f3dceaf0a984518966928a87d5626f2fa3836d1673cc2514c9838dfbc",
            "originalResponseUri": "ni:///sha-256;viikLz3OrwqYRRiWaSiofVYm8vo4NtFnPMJRTJg437w",
            "normalizedLotDigest": "sha256:2c5f3428371101732140a1f82e64e981b1bf3b50fb869c5de239ff9c59bd4335",
            "observedAt": "2026-11-12T21:30:47.088Z",
            "provider": "https://www.federalregister.gov",
            "publisher": {
              "name": "Office of the Federal Register",
              "source": "https://www.federalregister.gov/reader-aids/developer-resources/rest-api",
              "reproduction": "https://www.archives.gov/federal-register/faqs",
              "officialNotice": "The source Federal Register edition, not this derived JSON, is authoritative. No government endorsement."
            },
            "evidenceClass": "source-dated government metadata, independently replayable from original HTTP bytes held by the source acquisition run"
          }
        }
      },
      "time": {
        "asserted": "2026-11-12T21:30:47.088Z"
      },
      "force": "quotes",
      "provenance": {
        "witness": "https://www.federalregister.gov",
        "method": "quoted collector metadata from an original HTTP response",
        "citation": "https://www.federalregister.gov/documents/2026/11/12/2026-22970/early-phase-ind-protocol-recommendations-for-solid-tumors-draft-guidance-for-industry-availability",
        "sourceDigest": "sha256:be28a42f3dceaf0a984518966928a87d5626f2fa3836d1673cc2514c9838dfbc"
      },
      "status": "unverified"
    },
    {
      "id": "editorial-standing",
      "proposition": {
        "predicate": "editorial-standing",
        "object": "source metadata; editorial acceptance pending"
      },
      "time": {
        "asserted": "2026-11-12T21:30:47.088Z"
      },
      "force": "quotes",
      "provenance": {
        "witness": "https://www.federalregister.gov",
        "method": "quoted collector metadata from an original HTTP response",
        "citation": "https://www.federalregister.gov/documents/2026/11/12/2026-22970/early-phase-ind-protocol-recommendations-for-solid-tumors-draft-guidance-for-industry-availability",
        "sourceDigest": "sha256:be28a42f3dceaf0a984518966928a87d5626f2fa3836d1673cc2514c9838dfbc"
      },
      "status": "unverified"
    }
  ]
}
